MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$14,969K
EPS
-$0.39
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
11,648 12,687* 10,992 NaN
General and administrative
5,256 4,717* 3,940 NaN
Other segment items
NaN NaN NaN 167
Total operating expenses
16,904 17,404 14,932 NaN
Research and development-Unallocated Internal Costs
NaN NaN NaN 3,338
Loss from operations
-16,904 -17,404* -14,932 NaN
Research and development-PIPE791
NaN NaN NaN 6,178
Interest income
2,505 892* NaN NaN
Research and development-PIPE307
NaN NaN NaN 2,160
Change in fair value of warrant liability
NaN 0* NaN NaN
Research and development-Discovery Programs
NaN NaN NaN 1,328
Other expense, net
-57 -41* NaN NaN
Research and development-CTX343
NaN NaN NaN 1,059
Total other income, net
2,448 851* 2,410 NaN
Interest income
NaN NaN NaN 2,029
Net loss
-14,456 -16,553* -12,792 NaN
General and administrative
NaN NaN NaN 3,839
Unrealized loss (gain) on marketable securities
-513 -165* 118 NaN
Net loss
NaN NaN NaN -16,040
Comprehensive loss
-14,969 -16,718 -12,674 NaN
Basic EPS
-0.39 -0.613 -0.45 NaN
Diluted EPS
-0.39 -0.604 NaN NaN
Basic Average Shares
37,339,026 27,286,162 28,115,548 NaN
Diluted Average Shares
37,339,026 27,700,855 NaN NaN
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Comprehensive loss-$14,969K Interest income$2,505K Net loss-$14,456K Unrealized loss (gain) onmarketable securities-$513K Total other income,net$2,448K Other expense, net-$57K Loss from operations-$16,904K Total operatingexpenses$16,904K Research and development$11,648K General andadministrative$5,256K

Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics, Inc. (CTNM)